- Original article
- Open Access
Pulmonary fibrosis as a risk factor for thromboembolic disease
Egyptian Journal of Bronchology volume 9, pages 160–164 (2015)
Chronic obstructive pulmonary disease (COPD) and lung cancer are well known to be associated with increased risk for venous thromboembolism (VTE). However, there are few data about the association between idiopathic pulmonary fibrosis (IPF) and VTE.
Aim of this study
The aim of the study was to investigate the prevalence of venous thromboembolic events in hospitalized IPF patients and compare it with the incidence in COPD patients.
Patients and methods
We retrospectively analyzed the database of interstitial lung disease from 2007 to 2013. We included 629 IPF patients after exclusion of patients with secondary pulmonary fibrosis and those with a concurrent diagnosis of COPD or lung cancer. VTE disease was defined as either deep venous thrombosis, pulmonary embolism, or both deep venous thrombosis and pulmonary embolism. For comparison, we also analyzed the database of COPD patients.
Out of the 629 included IPF patients, 13 had thromboembolic events, showing a prevalence for VTE in IPF that is significantly higher than that in COPD (2.1 vs. 1.1%; odds ratio: 1.9; confidence interval: 1.039–3.530; P = 0.035). The prevalence is also significantly higher in female and nonsmoker IPF patients compared with COPD patients (P = 0.008 and 0.011 respectively). Among IPF patients, men had significantly lower risk for VTE compared with women (P = 0.045).
IPF, especially in women, is associated with increased risk for VTE, being greater than the risk in COPD.
Gunen H, Gulbas G, In E, Yetkin O, Hacievliyagil SS. Venous thromboemboli and exacerbations of COPD. Eur Respir J 2010; 35:1243–1248.
Ahmet U, Mehmet K, Esra U, Selma Y, Funda C, Ercüment E. Prognostic significance of plasma D-dimer levels in patients with lung cancer. Eur J Gen Med 2010; 7:155–160.
Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ, American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141(Suppl):7S–47S.
Fihn SD, Gardin JM, Abrams J, Berra K. American College of Cardiology Foundation/American Heart Association Task Force, et al. ACCF/ AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126:354–471.
Olman MA, Mackman N, Gladson CL, Moser KM, Loskutoff DJ. Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse. J Clin Invest 1995; 96:1621–1630.
Imokawa S, Sato A, Hayakawa H, Kotani M, Urano T, Takada A. Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. Am J Respir Crit Care Med 1997; 156(Pt 1):631–636.
Kobayashi H, Gabazza EC, Taguchi O, Wada H, Takeya H, Nishioka J, et al. Protein C anticoagulant system in patients with interstitial lung disease. Am J Respir Crit Care Med 1998; 157(Pt 1):1850–1854.
Fujii M, Hayakawa H, Urano T, Sato A, Chida K, Nakamura H, Takada A. Relevance of tissue factor and tissue factor pathway inhibitor for hypercoagulable state in the lungs of patients with idiopathic pulmonary fibrosis. Thromb Res 2000; 99:111–117.
Gunther A, Mosavi P, Ruppert C, Heinemann S, Temmesfeld B, Velcovsky HG, et al. Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Thromb Haemost 2000; 83:853–860.
Kubo H, Nakayama K, Yanai M, Suzuki T, Yamaya M, Watanabe M, Sasaki H. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005; 128:1475–1482.
Hubbard RB, Smith C, Le Jeune I, Gribbin J, Fogarty AW. The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am J Respir Crit Care Med 2008; 178:1257–1261.
Sprunger DB, Olson AL, Huie TJ, Fernandez-Perez ER, Fischer A, Solomon JJ, et al. Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease. Eur Respir J 2012; 39:125–132.
Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. ATS/ ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788–824.
Sode BF, Dahl M, Nielsen SF, Nordestgaard BG. Venous thromboembolism and risk of idiopathic interstitial pneumonia: a nationwide study. Am J Respir Crit Care Med 2010; 181:1085–1092.
Nathan SD, Barnett SD, Urban BA, Nowalk C, Moran BR, Burton N. Pulmonary embolism in idiopathic pulmonary fibrosis transplant recipients. Chest 2003; 123:1758–1763.
Garcia-Salcedo JA, de la TorreMM, Delgado M, Paradela M, Fieira EM, Gonzalez D, et al. Complications during clinical evolution in lung transplantation: pulmonary embolism. Transplant Proc 2010; 42:3220–3221.
Stein, PD, Beemath, A, Meyers FA, Olson RE. Pulmonary embolism and deep venous thrombosis in hospitalized adults with chronic obstructive pulmonary disease. J Cardiovasc Med (Hagerstown) 2007; 8:253–257.
Chen WJ, Lin CC, Lin CY, Chang YJ, Sung FC, Kao CH, Yeh JJ. Pulmonary embolism in chronic obstructive pulmonary disease: a population-based cohort study. COPD 2014; 11:438–443.
Mispelaere D, Glerant JC, Audebert M, Remond A, Sevestre-Pietri MA, Jounieaux V. Pulmonary embolism and sibilant types of chronic obstructive pulmonary disease decompensations. Rev Mal Respir 2002; 19:415–423.
Tillie-Leblond I, Marquette CH, Perez T, Scherpereel A, Zanetti C, Tonnel AB, Remy-Jardin M. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med 2006; 144:390–396.
Holst AG, Jensen G, Prescott E. Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study. Circulation 2010; 121:1896–1903.
Yarnell JW, Sweetnam PM, Rumley A, Lowe GD. Lifestyle and hemostatic risk factors for ischemic heart disease: the Caerphilly Study. Arterioscler Thromb Vasc Biol 2000; 20:271–279.
Lee KW, Lip GY. Effects of lifestyle on hemostasis, fibrinolysis, and platelet reactivity: a systematic review. Arch Intern Med 2003; 163:2368–2392.
Chambers RC. Procoagulant signaling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? Br J Pharmacol 2008; 153:367–378.
Collard HR, Calfee CS, Wolters PJ, Song JW, Hong SB, Brady S, et al. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2010; 299:3–7.
About this article
Cite this article
Farghaly, S., El-Abdin, A.Z. Pulmonary fibrosis as a risk factor for thromboembolic disease. Egypt J Bronchol 9, 160–164 (2015). https://doi.org/10.4103/1687-8426.158056
- idiopathic pulmonary fibrosis
- venous thromboembolism